Pharma Mar SA (ES:PHM)
BME:PHM
Want to see ES:PHM full AI Analyst Report?
PHM Stock Chart & Stats
€97.35
€0.65(0.83%)
At close: 4:00 PM EST
€97.35
€0.65(0.83%)
Day’s Range― - ―
52-Week Range€70.10 - €105.20
Previous CloseN/A
Volume4.24K
Average Volume (3M)74.16K
Market Cap
€1.49B
Enterprise Value€1.73B
Total Cash (Recent Filing)€167.85M
Total Debt (Recent Filing)€47.54M
Price to Earnings (P/E)17.9
Beta0.87
Next Earnings
Aug 05, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)4.65
Shares Outstanding18,000,000
10 Day Avg. Volume71,270
30 Day Avg. Volume74,161
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€120.50Price Target Upside23.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.35
Revenue Forecast (FY)€221.41M
Bulls Say, Bears Say
Bulls Say
High MarginsSustained very high trailing gross and net margins reflect strong product-level pricing power and low COGS for its oncology portfolio. Durable margin advantage supports internal R&D funding, partner negotiations and provides a cushion vs. revenue swings, enhancing medium-term financial resilience.
Sharp Revenue ReboundA large TTM revenue rebound indicates the company has regained commercial traction or realized milestone monetization, improving scale economics. Strong top-line recovery increases predictability of mid-term cash flows and supports continued investment in pipeline and commercialization capability.
Conservative Leverage & Cash GenerationLow debt relative to equity combined with solid recent operating and free cash flow gives the company flexibility to fund clinical programs and partnerships without pressing refinancing needs. This balance-sheet strength lowers financial risk and supports durable strategic optionality.
Bears Say
Earnings VolatilitySignificant through-the-cycle volatility in revenue and profits demonstrates earnings are not consistently stable. Such historic swings impede long-term planning for R&D and commercialization, make cash flow forecasting harder, and raise the risk that future setbacks could quickly erode margins.
Binary Dependence On Trials And MilestonesRevenue and earnings materially hinge on clinical, regulatory and partner milestone events. This structural dependence creates lumpy, binary revenue streams that reduce visibility, increase execution risk for multi-quarter planning, and make sustainable organic growth harder to predict.
Inconsistent Cash ConversionDespite recent FCF improvement, operating cash consistently trailed earnings and free cash was negative in prior years. This inconsistent cash conversion history can limit reliable reinvestment in the pipeline or shareholder returns unless the company sustains improved cash generation going forward.
Pharma Mar SA News
PHM FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was €70.10 and its highest was €105.20 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is €1.49B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Aug 05, 2026 which is in 56 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Apr 23, 2026. The company reported €0.088 earnings per share for the quarter, beating the consensus estimate of €0.008 by €0.08.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays a Annually dividend of €0.8 which represents an annual dividend yield of 1.04%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 0.22.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of €0.088 in its last earnings report, beating expectations of €0.008. Following the earnings report the stock price went up 3.083%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in ES:PHM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€120.50 (23.78% Upside)
€120.50 (23.78% Upside)
Insider Transactions
Bought Shares
Worth €10.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.08%
12-Months-Change
Fundamentals
Return on Equity
35.74%
Trailing 12-Months
Asset Growth
23.22%
Trailing 12-Months
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
PHM Company Deck
PHM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all ES:PHM earnings summariesPHM Stock 12 Month Forecast
Average Price Target
€120.50
▲(23.78% Upside)
Technical Analysis
Laboratorios Farmaceuticos Rovi
―
Oryzon Genomics SA
―
―
1nKemia IUCT Group SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---